276.66 sec. 001 - Topics in Pharmaceutical Policy: the Case of Biotherapeutics (Spring 2020)
Instructor: Rachel Zuraw
View all teaching evaluations for this course - degree students only
Due to COVID-19, law school classes were graded as credit/no pass in spring 2020.
- W 3:35 PM - 5:25 PM
Location: Law 10
From January 15, 2020
To February 26, 2020
Course End: February 26, 2020
Class Number: 32017
Enroll Limit: 29
As of: 06/16 11:02 PM
This course will spark discussion of the growing industry of biotherapeutics, which has been widely hailed as the fastest-growing sector in the pharmaceutical industry. In 2017, revenues from biotherapeutics were estimated at $163 billion. Given that biologics (treatments derived from living cells) make up more than 50% of drugs currently in development, this is only predicted to increase.
So, why have this course at a law school? Biologics are taking off at a time when we are wrestling with global intellectual property rights in the pharmaceutical industry. In this course we will use case studies from the United States, the European Union, and India to explore the impact of the gaps, conflicts, and overlaps in different countries’ patent systems on the pricing of pharmaceutical products. Students will learn to consider and compare different methods of intellectual property protection for biologic drugs, as well as how to apply ethical frameworks to consider their impact.
This course has no prerequisites; there will be an overview at the outset of the patentability of biologic products that will provide a sufficient basis for the expected level of discussion. The course is particularly designed to benefit and seek input from students with international practice experience, though both LL.M. and J.D. students are encouraged to enroll.
Professor Zuraw earned her J.D. and Master's in Bioethics from the University of Pennsylvania, and has taught courses in law and bioethics at Drexel University Thomas R. Kline School of Law and the University of Pennsylvania School of Arts and Sciences. She subsequently practiced at firms in the Bay Area for several years in the areas of health care and complex intellectual property litigation. Professor Zuraw's current scholarship is focused on drug pricing and accessibility.
Attendance at the first class is mandatory for all currently enrolled and waitlisted students; any currently enrolled or waitlisted students who are not present on the first day of class (without prior permission of the instructor) will be dropped. The instructor will continue to take attendance throughout the add/drop period and anyone who moves off the waitlist into the class must continue to attend in order not to be dropped.
Exam Notes: (T) Course ends in a final practice trial, arguments, or other presentation (e.g. Powerpoint)
This is a credit only course
Course Category: Intellectual Property and Technology Law
If you are the instructor or their FSU, you may add a file like a syllabus or a first assignment to this page.
Instructor has indicated that no books will be assigned.